Key takeaways
- Under the 2009 shared definition, you have metabolic syndrome if you meet three of five cutoffs: a large waist, triglycerides of 150 mg/dL or more, low HDL cholesterol, blood pressure of 130/85 or more, or fasting glucose of 100 or more, with medicine for any of them counting3.
- In national exam data from 2011 to 2016, 34.7% of U.S. adults met the ATP III version of the test, including 48.6% of those 60 and older4.
- In 2005 the American Diabetes Association and its European counterpart urged doctors to stop treating the syndrome as a distinct condition and to treat each risk factor instead5.
- In a trial published in 2025, 27.8% of adults with the syndrome who joined a habit-building program no longer met the criteria two years later, versus 21.2% who got monthly tip sheets, about 7 more people per 100 by our math8.
- The American Heart Association now counts metabolic syndrome as part of stage 2 in a wider “cardiovascular-kidney-metabolic” framework that it says covers about 90% of U.S. adults, and drug companies sponsor the initiative that promotes it7.
In 1988, researcher G. M. Reaven used a prestigious talk, the Banting lecture, to describe a pattern he called “Syndrome X”3. In his account, insulin resistance traveled with trouble handling sugar, unhealthy blood fats and high blood pressure3.
Belly fat wasn’t on his list3. Today a large waist sits at the top of most checklists, and the cluster has a plainer name: metabolic syndrome13.
The idea is simple. A few common measurements, each modest alone, tend to show up together and flag a higher chance of heart disease and type 2 diabetes3.
The label has also been fought over for two decades. Diabetes groups argued in 2005 that it added little to its parts5. Heart groups later folded it into a bigger frame that covers most American adults7.
If you’re wary of medical labels, that history is worth knowing. Here are the five numbers, what the bundle can and can’t tell you, and what moves each one.
Three of five ordinary numbers make the diagnosis
The name and the three-of-five rule came from the National Cholesterol Education Program’s 2001 guideline, known as ATP III13. Back then, the fasting glucose cutoff was 110 mg/dL1. The American Heart Association and the National Heart, Lung, and Blood Institute (NHLBI) lowered it to 100 in 20053.
Different groups wrote competing versions. The International Diabetes Federation, for example, required a large waist plus two other problems3. In 2009, six groups, including the federation, NHLBI and the American Heart Association, issued a joint statement that harmonized the definitions3.
Under that shared version, waist is one item of five, not a requirement3. Medicine counts: if you take a pill for blood pressure, triglycerides, HDL or blood sugar, that item counts as met3.
Waist cutoffs depend on ancestry. In the U.S., NHLBI counts a waist of more than 40 inches (102 cm) for men or more than 35 inches (88 cm) for women12. The American Heart Association uses 90 cm for men and 80 cm for women of Asian ancestry, about 35.4 and 31.5 inches by our math7.
The reason is body build. South Asians tend to carry more fat around their organs at a given waist size3. NHLBI notes that clinicians may use different cutoffs by race and ethnicity2.
About a third of U.S. adults qualify, and young adults are catching up
The best recent national snapshot is a 2020 JAMA analysis by researchers G. Hirode and Robert J. Wong of 17,048 adults in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 20164. They used the ATP III criteria4.
Overall, 34.7% had metabolic syndrome4. The share rose from 32.5% in 2011–2012 to 36.9% in 2015–2016, though that overall trend fell short of statistical significance4.
Some groups changed faster:
- Young adults: Among people 20 to 39, the share climbed from 16.2% to 21.3%, a significant rise4.
- Older adults: Across the six years, 48.6% of adults 60 and older met the criteria4.
- Women: The share rose from 31.7% to 36.6%4.
- Asian Americans: The share rose from 19.9% to 26.2%. The team didn’t apply race-specific waist cutoffs, which the authors said may have skewed the estimates, especially for Asian adults4.
We couldn’t confirm a peer-reviewed national estimate newer than 2016.
Weight and the syndrome don’t line up neatly. A 2017 review cited estimates that about 30% of adults with overweight and 60% of adults with obesity meet the criteria10. That means many larger people don’t. A later article in this series covers body weight and metabolic health.
Diabetes experts asked whether the label adds anything
In 2005, the American Diabetes Association and the European Association for the Study of Diabetes published a joint critique5. In their view, the criteria were vague, and nobody had shown where the cutoffs belonged5.
They questioned whether insulin resistance really ties the cluster together, and why diabetes, a major heart risk on its own, was counted inside it5. They also found no extra heart risk from the bundle beyond what its pieces carried separately, and no treatment for it other than treating each piece5.
So they told clinicians to drop the syndrome as a diagnosis to hunt for and to manage each heart risk factor directly5.
Within a month, the American Heart Association and NHLBI published a statement defending the concept5. Reviewing the fight in 2006 in the Canadian Journal of Cardiology, physicians Alice Cheng and Lawrence Leiter argued that the two sides agreed more than they differed5. All agreed it wasn’t a distinct disease and that its cause was unclear5.
A 2008 World Health Organization expert group went further. It judged the syndrome of limited practical use and called it a condition that comes before disease rather than a diagnosis in itself3.
What does it predict? In one study comparing definitions, every major version predicted both heart disease and type 2 diabetes, and the 2009 version predicted heart disease better than its parts added up or the Framingham risk score3. A large 2010 analysis linked the syndrome to about twice the risk of a heart attack10.
Relative numbers like “twice the risk” depend on where you start. Picture two people whose 10-year heart risk would otherwise be 2% and 10%. Doubling would mean 4% for one and 20% for the other, by our math. That’s an illustration, not a measured result, and it’s why your clinician also looks at a full risk calculator.
Heart groups widened the frame in 2023 and made it a guideline in 2026
In October 2023, the American Heart Association published a presidential advisory defining cardiovascular-kidney-metabolic (CKM) syndrome6. It describes how obesity, type 2 diabetes, chronic kidney disease and heart disease overlap6.
The advisory sorts people into five stages67:
- Stage 0: no risk factors.
- Stage 1: excess or belly fat, or prediabetes. The suggested goal is losing at least 5% of body weight6.
- Stage 2: type 2 diabetes, high blood pressure, high triglycerides, kidney disease or metabolic syndrome itself67.
- Stage 3: early heart disease without symptoms, or a high predicted risk6.
- Stage 4: diagnosed heart disease, such as a past heart attack, stroke or heart failure6.
By the association’s count, a third of U.S. adults have three or more of these risk factors6. Its 2026 implementation guide says about 90% of adults meet the criteria for CKM syndrome7.
Other estimates land nearby. A June 2026 preprint, not yet peer reviewed, put stage 1 or higher at 87.9% of adults in 2021–2023 national exam data12. A 2025 study of self-reported survey data found 79.5% in 2023, ranging from 71.8% in Colorado to 86.7% in West Virginia11.
On June 9, 2026, the American Heart Association and the American College of Cardiology released the first clinical guideline for CKM syndrome, with the American Diabetes Association and the American Society of Nephrology collaborating9. For the first time, it recommended GLP-1-based medicines for select people with obesity or type 2 diabetes and other heart risk factors9. It also calls for screening for needs such as food insecurity9.
Follow the money here, as you would anywhere. The implementation guide lists Novo Nordisk and Boehringer Ingelheim as founding sponsors, with Novartis, Bayer and the dialysis company DaVita also supporting7. The same guide estimates that more than 130 million U.S. adults may be eligible for CKM-related medicines, about 95% of them for weight treatment alone7.
Readers worried about medicalization have a point when a “syndrome” covers nearly 9 in 10 adults. The case on the other side is real too: the framework pushes for earlier kidney and liver checks7.
Your five-number check
This tool is our own, built from the 2009 shared criteria and American Heart Association guidance. Fill in your latest numbers. Three or more boxes in the “counts” column means metabolic syndrome. Two means it’s worth watching.
| Measure | Counts toward the syndrome if | Your number | What moves it |
|---|---|---|---|
| Waist | More than 40 in (102 cm) for men or 35 in (88 cm) for women12; for Asian ancestry, 90 cm or more (men) or 80 cm or more (women)7 | ______ | Losing weight, especially from the belly113 |
| Triglycerides | 150 mg/dL or more, or on treatment3 | ______ | Weight loss improves blood fats13; see our triglycerides article |
| HDL cholesterol | Under 40 mg/dL for men or under 50 for women, or on treatment3 | ______ | Weight loss improves blood fats13; see our cholesterol panel article |
| Blood pressure | 130 top number or 85 bottom number or higher, or on treatment3 | ______ | Weight loss lowers it13; see our blood pressure articles |
| Fasting glucose | 100 mg/dL or more, or on treatment3 | ______ | Weight loss lowers it13; habit training nudged it down in one trial8 |
If you meet three, ask your clinician about the checks the heart association’s guide recommends for stage 27:
- yearly kidney tests: a urine albumin test and a blood test of kidney filtration
- a liver-scarring score called FIB-4 every one to two years if you have diabetes, prediabetes or two or more metabolic risk factors, to check for damage from fatty liver disease
- a yearly recheck of all five numbers, compared with every two to three years at stage 1 and every three to five years at stage 0
A later article in this series covers kidney and liver markers in detail.
Habits can reverse it, and the trials show how much
The first guideline to name the syndrome put weight management and physical activity ahead of medicine, with drugs added for risk factors that persisted1. That is close to the natural-health instinct to fix the cause first, and the trials below suggest the instinct has support.
Prevention has strong support. In the Diabetes Prevention Program, the intensive lifestyle arm, aiming for 7% weight loss and 150 minutes of activity a week, cut new cases of metabolic syndrome by 41% compared with placebo3.
The newest test aimed at undoing the syndrome, not just preventing it. Lynda Powell of Rush University and colleagues ran the ELM trial at five U.S. sites, with 618 adults who already had metabolic syndrome8. Everyone got education and a Fitbit activity tracker8.
Half also joined a six-month program of 19 group meetings plus dietitian visits, followed by monthly support for 18 months8. The program built four habits: vegetables at meals, a daily brisk walk, paying attention to the senses, and pausing before reacting8. The other half got monthly tip sheets and a phone call every three months8.
After two years, 27.8% of the program group no longer met the criteria, versus 21.2% of the tip-sheet group8. By our math, that’s about 7 more people per 100, or one extra success for every 15 people in the program. The trial reported no safety concerns8.
A grant from a private charity, the William G. McGowan Charitable Fund, paid for the trial, with extra money from Rush and the Rochester Institute of Technology. The funders had no role in running it8.
Fasting glucose ended a little lower in the program group, 97.7 versus 100.7 mg/dL, and fewer took blood pressure medicine, 62.7% versus 71.5%8. Weight and waist differences weren’t statistically significant8.
Two caveats. About three-quarters of the volunteers were women, and most were white, so results may differ for other groups8. And a fifth of the tip-sheet group also left the syndrome behind, a reminder that these numbers move.
Weight loss helps every item on the list. NHLBI’s obesity guidance found that weight loss lowers blood pressure and blood sugar and improves blood fats, and it set an initial goal of about 10% over six months13. The heart association suggests at least 5% at stage 16. Our article on healthy eating patterns covers a Nordic diet trial in people with features of the syndrome.
When one number stays high, treating it makes sense: blood pressure medicine, statins and glucose-lowering drugs each have a role39. Lifestyle and medicine aren’t rivals here. Each number can be worked on both ways.
How strong is the evidence?
| Claim | Evidence level | What the research shows |
|---|---|---|
| The five measures cluster and predict heart disease and type 2 diabetes | In one comparison, all major definitions predicted both; about twice the heart attack risk310 | |
| The label predicts more than its parts added up | One comparison says yes for heart disease, not diabetes; the 2005 critique says no35 | |
| Structured lifestyle programs prevent the syndrome | Diabetes Prevention Program: 41% fewer new cases3 | |
| Habit programs reverse an existing syndrome | ELM: 27.8% vs. 21.2% at two years8 | |
| Waist size adds information beyond BMI | NHLBI guidance, most useful below a BMI of 3513 | |
| Being told you have “the syndrome” changes how each number is treated | Critics say treatment is the same either way35 |
When to get help
Metabolic syndrome raises heart risk, so know the emergency signs. The National Institute of Diabetes and Digestive and Kidney Diseases lists these reasons to call 911 right away14:
- Possible heart attack: chest pain or pressure that lasts more than a few minutes or returns, pain or discomfort in an arm or shoulder, the back, neck or jaw, shortness of breath, or sweating or a lightheaded feeling.
- Possible stroke: sudden weakness or numbness of the face, arm or leg on one side, sudden confusion or trouble talking, dizziness or loss of balance, trouble seeing, or a sudden, severe headache.
For the slower problems, see your clinician if your check shows three or more of the five. Ask about the kidney, liver and blood sugar tests above7. If you already have diabetes, kidney disease or heart disease, ask how your stage shapes your plan.
Questions readers ask
Is metabolic syndrome a disease?
Not exactly. Even the groups that defend the label agree it isn’t one distinct disease with a known cause5. Think of it as a warning light made of five gauges, each worth fixing.
Can thin people have it?
Yes. Under the 2009 definition, a large waist is one of five items, not a requirement, so high blood pressure, high triglycerides and low HDL can be enough3.
Is CKM syndrome replacing metabolic syndrome?
No. In the heart association’s staging, metabolic syndrome is one of the stage 2 risk factors79. CKM adds kidney health and heart disease to the same picture.
Do I need medicine?
That depends on each number and your overall risk. The guideline that named the syndrome starts with weight and activity, then treats risk factors that persist1. The 2026 guideline adds GLP-1-based medicines for select people9.
The bottom line
Metabolic syndrome is a shorthand, not a separate disease. Five common numbers, a big waist, high triglycerides, low HDL, higher blood pressure and higher fasting sugar, tend to arrive together, and together they mark a higher chance of heart disease and type 2 diabetes. Experts still argue over whether the label adds much beyond its parts, and heart groups now fold it into a broader framework whose AHA initiative has drug-company sponsors.
The practical path isn’t in dispute. Know your five numbers, measure your waist the right way, and work on the ones that are off with food, movement, weight and, when needed, medicine. Trials show habits can move the numbers, sometimes enough to leave the syndrome behind.
Related reading
About this article
This article was researched using NHLBI guidelines and health pages, peer-reviewed studies and reviews, a randomized trial, American Heart Association statements and guidance, and one clearly labeled preprint, all listed below. It was reviewed in October 2026. It is general education and not medical, legal or financial advice.
Sources
- National Heart, Lung, and Blood Institute, National Cholesterol Education Program. “ATP III Guidelines At-A-Glance Quick Desk Reference.” NIH Publication No. 01-3305, May 2001. nhlbi.nih.gov
- National Heart, Lung, and Blood Institute. “Metabolic Syndrome: Diagnosis.” NIH, updated May 18, 2022. nhlbi.nih.gov
- Lam DW, LeRoith D. “Metabolic Syndrome.” Endotext, NCBI Bookshelf, updated February 11, 2019. ncbi.nlm.nih.gov
- Hirode G, Wong RJ. “Trends in the Prevalence of Metabolic Syndrome in the United States, 2011–2016.” JAMA, 2020;323(24):2526–2528 (PubMed Central). pmc.ncbi.nlm.nih.gov
- Cheng AYY, Leiter LA. “Metabolic syndrome under fire: Weighing in on the truth.” Canadian Journal of Cardiology, 2006;22(5):379–382 (PubMed Central). pmc.ncbi.nlm.nih.gov
- American Heart Association News. “Report redefines overlapping risks of heart and kidney diseases.” October 9, 2023. heart.org
- American Heart Association. “Cardiovascular-Kidney-Metabolic (CKM) Health Initiative: Implementation Guide.” March 10, 2026 (sponsored by Novo Nordisk, Boehringer Ingelheim, Novartis, Bayer and DaVita). heart.org
- Powell LH, Berkley-Patton J, Drees BM, et al. “Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial.” JAMA Internal Medicine, 2026;186(1):67–77, published online November 9, 2025. pubmed.ncbi.nlm.nih.gov
- American Heart Association Newsroom. “First-ever clinical guideline issued for cardiovascular-kidney-metabolic (CKM) syndrome.” June 9, 2026. newsroom.heart.org
- Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. “Cardiovascular Consequences of Metabolic Syndrome.” Translational Research, 2017;183:57–70 (PubMed Central). pmc.ncbi.nlm.nih.gov
- Chang R, Parekh T, Hagan KK, Javed Z, Ostrominski JW. “State-Level Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in the United States, 2011 to 2023.” JACC: Advances, 2025;4(6):101754 (PubMed Central). pmc.ncbi.nlm.nih.gov
- Fu F, Wei A, Wang G, et al. “Cardiovascular-Kidney-Metabolic Syndrome Among US Adults, 1999–2023: National Trends and Projections Through 2050.” medRxiv preprint, not peer reviewed, June 10, 2026. medrxiv.org
- National Heart, Lung, and Blood Institute Obesity Education Initiative and North American Association for the Study of Obesity. “The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.” NIH Publication No. 00-4084, October 2000. nhlbi.nih.gov
- National Institute of Diabetes and Digestive and Kidney Diseases. “Diabetes, Heart Disease, & Stroke.” NIH, reviewed April 2021. niddk.nih.gov